

HYPERKALAEMIA DESERVES MORE THAN JUST A QUICK FIX


Down-titrating RAASI in your CKD and HF patients is a strategy that can increase mortality risk.

Save the date

For AstraZeneca's Hyperkalaemia and RAASi Europe Solutions Summit

Dear Sir/Madam,

Please save the date for AstraZeneca's Hyperkalaemia and RAASi Europe Solutions Summit:



Wednesday 21st September 2022 at 19:00 CEST

RAASi therapy is recommended by the 2021 KDIGO Clinical practice guideline for the management of blood pressure in chronic kidney disease (CKD)¹ for patients with CKD and by the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure (HF)² for patients with HF to reduce the risk of morbidity and mortality. Despite updates to recent global guidelines stating that RAASi down-titration should be a last resort, this strategy is commonly used to manage hyperkalaemia.



Why is RAASi still regularly down-titrated in the management of hyperkalaemia and what strategies can be put in place to prevent this from happening?

We want to know your thoughts!

Do not miss this exciting opportunity to participate in a global solutions summit where healthcare professionals from different countries will come together to discuss RAASi therapy modification and hyperkalaemia management in cardiorenal patients.

Dr Andrew Frankel (Imperial College Healthcare NHS Trust, London, UK) and **Professor Andrew Coats** (University of Warwick, UK; Monash University, Melbourne, Australia) will be leading the discussion as our meeting chairs. They will be joined by a keynote speaker, behaviourist **Amy Brann** (founder and CEO of Synaptic Potential).

The objectives of the meeting are to identify:

-  Why RAASi therapy is being down-titrated due to hyperkalaemia in patients with cardiorenal disease
-  What behavioural strategies can be implemented to overcome the challenge of RAASi therapy down-titration due to hyperkalaemia in patients with cardiorenal disease

Discussions will be localised by country to explore how patients can remain on guideline directed RAASi therapy, with interactive workshops focused on problem identification and solutions. Importantly, we will examine the outcomes of the localised discussions to identify common and country-specific themes.

Registration for the event is now live; please [click here](#) to sign up for the event.

We look forward to welcoming and collaborating with you at this meeting.

Kind regards,

Hyperkalaemia Solutions Summit Europe team

This is a non-promotional scientific exchange meeting. This meeting is organised and funded by AstraZeneca.
References: 1. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. *Kidney Int* 2021;99(3S):S1–S87. 2. McDonagh TA, et al. *Eur Heart J* 2021;42:3599–3726.

